-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On January 18, Colum Pharmaceuticals announced that the company recently obtained the approval of the State Drug Administration issued the chemical "medium/long-chain fat emulsion" of the "Drug SupplementAl Application Approval Notice", the drug through generic quality and efficacy consistency evaluation, to provide energy and essential fatty acids for patients in need of intravenous nutrition.
intestinal nutrition plays an important role in the treatment of patients with critical injury and severe trauma, which can quickly provide the nutrients needed by the body, promote the recovery of patients and improve the prognostics of the disease.
At present, our company has been approved to market 8 new intestinal nutrition products, covering single bags, two-room bags, three cavity bags in different packaging forms, and because of differentiated product formulations clinically can meet different types (liver function impairment, peri-surgical period, critical illness, etc.) and different energy needs of patients nutritional treatment.
medium/long chain fat emulsion is the most widely used fatty milk in clinical practice, with rapid energy supply, high efficiency nitrogen saving, liver protection and other advantages, has been widely recommended by domestic and foreign guidelines for liver function damage and tumor and other patients.
/long-chain fat emulsion (C8-24Ve) is the 2020 edition of the National Health Insurance Directory, with sales of 780 million yuan in China in 2019.
this time our company's first domestic through the consistent evaluation, will further enhance the market competitiveness of the species.
addition, with the product through the first domestic consistent evaluation, and the follow-up series of varieties continued to be approved, our company will become a complete category, the domestic leading out-of-intestinal nutrition system solutions suppliers.